PRESS RELEASE published on 09/05/2024 at 07:30, 1 year 11 months ago Inside Information / Other news releases Teva provides update on pivotal Phase 3 of Olanzapine LAI by Medincell. Safety results on track for H2 2024. Potential innovative long-acting antipsychotic treatment Clinical Trials Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 08/20/2024 at 17:52, 1 year 11 months ago Terms of participation in the Medincell General Meeting Shareholders General Assembly Remote Voting Medincell Videoconference
PRESS RELEASE published on 08/20/2024 at 17:47, 1 year 11 months ago Terms of availability of the preparatory documents for the GM Medincell announces participation terms in the Combined General Meeting on September 12, 2024, including remote voting options, video conference for shareholders, and document availability Shareholders Combined General Meeting Remote Voting Medincell Participation Terms
BRIEF published on 06/28/2024 at 07:35, 2 years 1 month ago H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation FDA Approval BUY Rating Biopharmaceuticals H.C. Wainwright & Co. Medincell
PRESS RELEASE published on 06/28/2024 at 07:30, 2 years 1 month ago Inside Information / Other news releases H.C. Wainwright & Co. initiates coverage of MedinCell with a 'Buy' recommendation at €24 price target, reflecting +80% potential increase. MedinCell achieves milestones with FDA approvals, positive Phase 3 results, and collaboration with AbbVie FDA Approval Coverage Initiation H.C. Wainwright & Co. Medincell Pharmaceutical Sector
BRIEF published on 06/11/2024 at 09:05, 2 years 2 months ago Medincell Joins Euronext Tech Leaders Index Innovation Tech Sector Investor Visibility Medincell Euronext Tech Leaders
PRESS RELEASE published on 06/11/2024 at 09:00, 2 years 2 months ago Inside Information / Other news releases Medincell joins Euronext Tech Leaders, gaining access to a broad investor base and support services. CEO Christophe Douat highlights the company's growth and tech innovation leadership Tech Sector Financial Strategy Investor Base Medincell Euronext Tech Leaders
BRIEF published on 05/10/2024 at 18:05, 2 years 3 months ago Medincell announces details on capital and voting rights in accordance with regulations Euronext Paris Share Capital Voting Rights Financial Regulation Medincell
BRIEF published on 05/08/2024 at 12:35, 2 years 3 months ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
PRESS RELEASE published on 05/08/2024 at 12:30, 2 years 3 months ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
Published on 08/12/2026 at 00:00, 7 hours 48 minutes ago Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 8 hours 8 minutes ago RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 8 hours 33 minutes ago Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/11/2026 at 23:00, 8 hours 48 minutes ago Prospectiva Resources Ltd. Completes Qualifying Transaction
Published on 08/11/2026 at 22:55, 8 hours 53 minutes ago NV Gold Announces Non-Brokered Private Placement
Published on 08/12/2026 at 07:30, 18 minutes ago BIKE24 continues growth trajectory in the second quarter of 2026 and strengthens its position in the European market
Published on 08/12/2026 at 07:30, 18 minutes ago wienerberger strengthens its position in infrastructure and renovation – Q2 2026 results
Published on 08/12/2026 at 07:30, 18 minutes ago Sensirion’s SGM5304 gas meter module successfully achieves EN 17526 certificatio
Published on 08/12/2026 at 07:30, 18 minutes ago GESCO recorded a solid performance in the first half of 2026 despite persistently challenging conditions
Published on 08/12/2026 at 07:30, 18 minutes ago Hannover Re generates very good half-year result and remains on track to achieve full-year guidance
Published on 08/10/2026 at 18:00, 1 day 13 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 1 day 19 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 1 day 20 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 1 day 22 hours ago Number of shares and voting rights - July 2026 (In French only)
